JP2015517496A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517496A5
JP2015517496A5 JP2015511575A JP2015511575A JP2015517496A5 JP 2015517496 A5 JP2015517496 A5 JP 2015517496A5 JP 2015511575 A JP2015511575 A JP 2015511575A JP 2015511575 A JP2015511575 A JP 2015511575A JP 2015517496 A5 JP2015517496 A5 JP 2015517496A5
Authority
JP
Japan
Prior art keywords
antibody
seq
set forth
domain
pnag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015511575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517496A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/039724 external-priority patent/WO2013169657A1/en
Publication of JP2015517496A publication Critical patent/JP2015517496A/ja
Publication of JP2015517496A5 publication Critical patent/JP2015517496A5/ja
Pending legal-status Critical Current

Links

JP2015511575A 2012-05-07 2013-05-06 バイオフィルム形成を防止する方法 Pending JP2015517496A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261643650P 2012-05-07 2012-05-07
US61/643,650 2012-05-07
FR1352399 2013-03-18
FR1352399 2013-03-18
PCT/US2013/039724 WO2013169657A1 (en) 2012-05-07 2013-05-06 Methods for preventing biofilm formation

Publications (2)

Publication Number Publication Date
JP2015517496A JP2015517496A (ja) 2015-06-22
JP2015517496A5 true JP2015517496A5 (enExample) 2016-06-23

Family

ID=52691156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511575A Pending JP2015517496A (ja) 2012-05-07 2013-05-06 バイオフィルム形成を防止する方法

Country Status (2)

Country Link
US (1) US20150086601A1 (enExample)
JP (1) JP2015517496A (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204876A1 (en) * 2017-05-04 2018-11-08 City Of Hope Antibody variable domains and antibody constructs
BR112022009924A2 (pt) * 2019-11-22 2022-08-09 Alopexx Inc Métodos para fornecer terapia contínua contra pnag compreendendo micróbios

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2468769A1 (en) * 2004-04-21 2012-06-27 The Brigham and Women's Hospital, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof

Similar Documents

Publication Publication Date Title
Ferraris et al. Antibacterial titanium surfaces for medical implants
WO2009043476A3 (en) Neuromedin s as a therapeutic agent
JP2014169326A5 (enExample)
WO2009033762A3 (en) Use of endothelin-3 as a therapeutic agent
UA107115C2 (uk) Тіоацетатні похідіні піридину, композиція на їх основі та їх застосування
WO2008144130A3 (en) Implantable medical devices with a topcoat layer of phosphoryl choline acrylate polymer for reduced thrombosis, and improved mechanical properties
WO2009046824A3 (en) Use of apelin-12 as a therapeutic agent, eg for treating excessive angiogenesis
JP2016527217A5 (enExample)
NZ596807A (en) Uses of immunoconjugates targeting cd138
WO2009039983A3 (en) Use of a peptide as a therapeutic agent
WO2009033789A3 (en) Use of a peptide as a therapeutic agent
WO2009033739A3 (en) Use of a peptide as a therapeutic agent
WO2008039722A3 (en) External catheter with antiseptic agent
WO2008091925A3 (en) Treatment of aortic dissection or aneurysm
BR112013028914A2 (pt) antagonistas de receptores de integrina e seus métodos de uso
WO2009033730A3 (en) Peptide gxgrgdspca as a therapeutic agent
WO2009040048A3 (en) Use of the c-reactive peptide as a therapeutic agent
WO2009033757A3 (en) Use of mage-3 antigen (271-279) as a therapeutic agent
WO2009040072A3 (en) Use of angiotensin i as a therapeutic agent in the treatment of eg aids or tuberculosis
WO2009046829A3 (en) Casoxin d as a therapeutic agent
WO2009040035A3 (en) Use of a peptide as a therapeutic agent
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
WO2011113507A3 (en) Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns
JP2020502198A5 (enExample)
JP2015522018A5 (enExample)